Source: Annual Congress 2009 - New insights in biology and treatment of pleural tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Hollevoet, E. Kellen, K. Nackaerts, L. Bosqueé, P. Germonpré, J. Delanghe, C. Legrand, J. P. van Meerbeeck (Ghent, Leuven, Liège, Antwerp, Louvain-la-Neuve, Belgium). Soluble mesothelin as a monitoring tool for malignant mesothelioma patients. Eur Respir J 2009; 34: Suppl. 53, 1798

Member's Comments

No comment yet.

Related content which might interest you: Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma Source: Annual Congress 2008 - Inorganic dust exposure and the lung Year: 2008 Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Integrated CT-PET is a valuable tool for staging malignant pleural mesothelioma Source: ISSN=ISSN 1810-6838, ISBN=, page=173 Year: 2005 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004 A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Source: Eur Respir J 2010; 36: 1099-1105 Year: 2010 Soluble mesothelin as an early diagnostic tool in asbestos-exposed workers Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions Source: Eur Respir J 2013; 41: 18-24 Year: 2013 Prognostic impact of histology and treatment modalities in malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Evaluating the utility of mesothelin in diagnosing mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001